IBJNews

Potential competitor to Lilly drug shows promise in study

Back to TopCommentsE-mailPrintBookmark and Share

Sanofi-Aventis SA’s experimental diabetes drug lixisenatide, given to volunteer patients once a day, was at least as effective as Eli Lilly and Co. and Amylin Pharmaceuticals Inc.’s twice-daily medicine Byetta in keeping blood-sugar levels in check, a study found.

The advanced study of 639 patients with the most common form of diabetes, known as Type 2, showed those taking the Sanofi drug also had fewer instances of hypoglycemia, a state of dangerously low blood sugar, Paris-based Sanofi said in a statement.

The findings could lead to more competition for Indianapolis-based Lilly, which markets Byetta outside the United States and co-markets it with Amylin in the U.S. The drug had worldwide sales of $796.5 million in 2009.

Diabetes occurs when the body doesn’t produce or properly use insulin, a hormone needed to convert sugar, starches and other food into the energy needed for daily life. Lixisenatide belongs to a class of drugs that imitate a hormone called GLP-1 to stimulate the pancreas to produce more insulin after meals. Both lixisenatide and Byetta are injections.

Sanofi trails Novo Nordisk A/S and Lilly in developing a GLP-1 product. Peter Welford, an analyst at Jefferies International Ltd., wrote in a note to investors Tuesday that he expects lixisenatide to have "blockbuster" sales. The full study will be released at a medical conference, the drugmaker said. Zealand Pharma A/S of Denmark developed lixisenatide from the spit of the Gila monster.

Byetta uses a synthetic version of a substance in Gila monster saliva.

Separately, Roche Holding AG said Tuesday that it’s stopping development of another GLP-1 treatment, taspoglutide, and returning rights to developer Ipsen SA.

After “extensive analysis,” the Switzerland-based company said it has decided to stop development of the medicine. Ipsen said it will sift through the Roche research and could seek another partner. The decision may mean the end of development for a drug that some analysts once predicted would have annual sales of more than $1.38 billion and compete with Byetta and Novo Nordisk’s Victoza.
 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT